PLT-EMPD-Supplemental Materials

Published: 26 May 2026| Version 1 | DOI: 10.17632/fhm79pnkcj.1
Contributor:
Kan Wu

Description

This dataset contains the de‑identified supplemental materials for “Primary Tumor Location Stratifies Second‑Primary Risk and Survival in Extramammary Paget’s Disease: A Population‑Based SEER Cohort Study.” It enables replication of all summary statistics and figures reported in the Brief Report. Contents Data dictionary (codebook) describing variables used in analyses. PTL mapping file: prespecified, mutually exclusive mapping from SEER primary site codes to four primary tumor locations (vulvar, penoscrotal, perianal, other cutaneous). Derived cohort table (counts only; no individual‑level microdata): site‑specific totals, event counts, and time‑to‑event summaries. Figure source data: cumulative incidence (Fine–Gray) by PTL, survival (Kaplan–Meier) by PTL, and sex‑stratified summaries for perianal and other cutaneous groups. Analysis notes: inclusion/exclusion rules, endpoint definitions, censoring rules, and model covariates. Data source and period SEER Research Database (US), cases from 2000–2022. Case definition: first primary EMPD (ICD‑O‑3 histology 8542/3). Exclusions: unclear site, unconfirmed pathology, age <18 years, follow‑up <1 month. Outcomes and methods Secondary malignancy: any malignant neoplasm diagnosed ≥1 month after EMPD; EMPD recurrences and same‑site different‑histology tumors excluded. Estimated with cumulative incidence functions and Fine–Gray models (death as competing risk). Survival: overall survival and cancer‑specific survival via Kaplan–Meier and multivariable Cox regression. Adjusted covariates: age, sex, race, marital status, year of diagnosis, SEER stage, tumor size, and initial treatment. Sex‑stratified analyses performed within perianal and other cutaneous PTLs (the only PTLs including both sexes). How to use Reproduce tables/figures by loading the figure‑source CSVs and codebook; apply the PTL mapping to SEER primary site codes as provided. Report absolute risks (5‑, 10‑, 15‑year cumulative incidence) alongside hazard ratios for interpretation. Ethics and privacy Only aggregate, de‑identified data are provided. Use complies with SEER data‑use terms. IRB review exempt; patient consent not applicable. Funding and contact Supported by the National Natural Science Foundation of China and Sichuan Provincial Natural Science Foundation. Correspondence: Kan Wu (wukanlzu@163.com)

Files

Institutions

Categories

Dermatology, Cancer

Licence